Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveFluconazole pharmacokinetics and safety in premature infantsFluconazole dosing for the prevention or treatment of invasive candidiasis in young infantsPopulation pharmacokinetics of fluconazole in young infants.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)Antifungal drug discovery: the process and outcomes.First three reported cases of nosocomial fungemia caused by Candida aurisThe use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingPosaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapyFluconazole loading dose pharmacokinetics and safety in infantsHow much European prescribing physicians know about invasive fungal infections management?Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.Antifungal pharmacokinetics and pharmacodynamicsFluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos NigeriaImpact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaOptimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisAssociation of fluconazole pharmacodynamics with mortality in patients with candidemiaIsavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antifungal therapeutic drug monitoring: established and emerging indications.Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.Safety of triazole antifungal drugs in patients with cancer.Opportunistic invasive fungal infections: diagnosis & clinical management.Pharmacokinetic evaluation of fluconazole in critically ill patients.Antifungal susceptibility testing: a primer for clinicians.The evolving role of antifungal susceptibility testing.Impact of new antifungal breakpoints on antifungal resistance in Candida speciesIn vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazoleRisk factors for fluconazole-resistant candidemia.The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region.
P2860
Q27009221-59F15358-7810-4EAD-B627-E1AD78F182C3Q27014816-AD672A87-DC66-4138-9B35-77DEC098B66EQ30435365-F50323AC-4E0C-48D0-86D5-A29AFF3D5877Q30439710-E0D075D8-87A3-41E1-B8C8-601EE78C3CE6Q30844731-B65BC465-C32D-4E3F-8DDA-0315681057D7Q30936281-0D4752A3-0B5B-4AC7-A233-9D3321016350Q33528384-696A7F35-AE46-4D98-9EB3-5D9F1810DDD1Q34086897-C2A7F35D-5B58-4D2D-B67B-94A8C215E55AQ34196357-85C908E0-00CD-4E95-8F12-21B9F497A3BDQ34480715-C69BA952-81DB-4BA9-84F4-B1AF74DEF5E8Q34597018-4F60B018-1913-4AE6-8E2D-00D21D85CE49Q34647337-4DAF405B-9346-415A-BE47-D1EE2CEDA7A6Q34737174-96060896-D9C8-4E4A-B9D7-7BB409340026Q34807770-351A5A61-4E6D-45C5-837E-6C88744F0602Q35131938-EF55D737-DEE3-40B4-9661-99C523FB3D5DQ35598414-CC136DAA-A337-4131-8361-FB4C4DB3D51DQ35635693-C514D9AF-C818-4F12-AF03-2F62DA3593A6Q35663841-6A1A9C8F-E181-49B1-A4FF-86E5C022DE2BQ35746253-3CF85818-B783-40AA-AAB7-DDCCB1848451Q35862713-B12DE163-65E5-4B5E-ACCC-B28E11985BB0Q36018860-112E89AD-2414-405E-8A82-6B63C0C7FA52Q36094974-A1C88B4C-97C3-411A-B556-7BA6C33A4E20Q36364100-EEF84385-9C93-43D1-B128-B8B73097CC70Q36505539-05AE576C-5C4E-4800-98B2-D8FB6174BD56Q36870712-AAC2088E-6C38-4876-8A27-7421CA7FF4C2Q37263435-E508FA91-48E3-452D-AC47-3324FC713BC8Q37310029-0F0A8953-D416-455F-AC08-63CD42D296A5Q37356974-6C875CB9-CD08-4C6B-AF96-409B6CF5580FQ37374850-698F5675-89D7-492C-95CA-D37466189807Q37521422-7A57F51C-4929-41F8-B64C-4C8B9BCE99C3Q37662650-C3246339-7D3B-4EFA-8F0B-D771DB9A217EQ37726198-0D17CE56-AB80-4EF7-8DEE-632D6587B8B4Q37924819-12D9C802-217E-41A3-9DD4-F5BDEB7429FDQ38061087-50884203-2197-400F-9257-0335CAA4C9FAQ38095809-F9667833-9EA4-4816-8726-7D150E349A98Q38323404-70E54665-BACD-4042-9E4F-B66E166BA1E6Q38664984-EC5D57D6-215F-4FF9-9E24-21898804BF45Q39934814-AAE46BD1-B1A1-4436-97F5-F55AF21835E5Q40045635-B06E00DF-8F48-4664-9BC6-CCF95AD333C8Q40118569-F31AB565-4E72-42F6-AB52-46A527F42051
P2860
Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Fluconazole MIC and the flucon ...... mong patients with candidemia.
@ast
Fluconazole MIC and the flucon ...... mong patients with candidemia.
@en
type
label
Fluconazole MIC and the flucon ...... mong patients with candidemia.
@ast
Fluconazole MIC and the flucon ...... mong patients with candidemia.
@en
prefLabel
Fluconazole MIC and the flucon ...... mong patients with candidemia.
@ast
Fluconazole MIC and the flucon ...... mong patients with candidemia.
@en
P2093
P2860
P1476
Fluconazole MIC and the flucon ...... among patients with candidemia
@en
P2093
Arthur J Morris
Cornelius J Clancy
M Hong Nguyen
Victor L Yu
P2860
P304
P356
10.1128/AAC.49.8.3171-3177.2005
P407
P577
2005-08-01T00:00:00Z